該当箇所へ

Genedata Provides R&D Knowledge Management System to Support Bayer Schering Pharma’s Biologics Research

Data management and analysis system supports key informatics tasks for biologics discovery at Bayer Schering Pharma centers across Europe and the US

January 5, 2010
Basel, Switzerland and Lexington, MA, USA

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, and Bayer Schering Pharma AG, one of the world’s leading global specialty pharmaceutical companies, today announced a multi-year collaboration for the development and implementation of the Biologics Data Platform (BDP). BDP will support biologics data management and analysis at Bayer Schering Pharma R&D sites worldwide, which are developing novel protein-based therapeutics for diseases such as cancer, hemophilia, and multiple sclerosis.

“The Biologics Data Platform is an important system for our daily operations as it makes the highly interconnected biologics R&D processes more efficient,” explained Dr. Heiner Apeler, director of Molecular and Antibody Biology at Bayer Schering Pharma. “The BDP supports our scientists in a complex, multi-site environment by providing all the necessary information and tools to streamline the biologics lead generation and optimization process. At the same time, the BDP will provide a complete historical record of our therapeutic proteins, which will be important for downstream biologics development.”

Comprehensive Platform Supports Complete Biologics R&D
The BDP provides a shared data storage and data exchange platform to synchronize Bayer Schering Pharma’s activities starting with biologics screening all the way through to production. Developed for both antibody-based and other protein therapeutics, the platform supports key informatics tasks from library generation and laboratory logistics to biologics registration and analytics. The platform directly interacts with laboratory equipment such as screening robots and integrates into Bayer Schering Pharma’s existing IT infrastructure.

“We are excited about the collaboration with Bayer Schering Pharma in the area of biologics R&D,” said Dr. Othmar Pfannes, CEO of Genedata. “Genedata has broad experience with biological sequence management, screening data analysis and other complex laboratory processes. As the market for protein therapeutics expands, the demand for new software to efficiently support the biologics R&D process is increasing and Genedata is well-positioned to provide cutting-edge solutions to our customers.”


The Biologics Data Platform makes the highly interconnected biologics R&D processes more efficient

Dr. Heiner Apeler
Director of Molecular and Antibody Biology